A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Deucrictibant (Primary)
- Indications Hereditary angioedema
- Focus Proof of concept; Therapeutic Use
- Acronyms CHAPTER-1; HAE CHAPTER-1
- Sponsors Pharvaris
- 04 Jun 2024 According to a Pharvaris media release, data from this study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024.
- 13 May 2024 According to a Pharvaris media release, company announced the acceptance of abstracts for presentation at the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024.
- 04 Apr 2024 According to a Pharvaris media release, efficacy and safety results from this trial will be presented at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.